Abstracts tagged "SLE and opioids"

Abstract Number: 2998 • 2018 ACR/ARHP Annual Meeting
Opioid Use Among SLE Patients and Controls in the Population-Based Michigan Lupus Epidemiology & Surveillance (MILES) Cohort
Jiha Lee¹, Amrita Padda², Wendy Marder³, Siobán Harlow⁴, Afton L. Hassett⁵, Suzanna Zick⁶, Charles G. Helmick⁷, Kamil E. Barbour⁷, Caroline Gordon⁸, Deeba Minhas³, W. Joseph McCune³ and Emily C. Somers³, ¹Rheumatology, University of Michigan School of Medicine, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Epidemiology Department- School of Public Health, Obstetrics and Gynecology- Medical School, University of Michigan, Ann Arbor, MI, ⁵Anesthesiology, University of Michigan, Ann Arbor, MI, ⁶Department of Family Medicine, University of Michigan, Ann Arbor, MI, ⁷Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ⁸Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: SLE patients frequently experience pain. Opioid use for the management of chronic pain has been associated with increased morbidity, mortality, and healthcare resource utilization.…
Abstract Number: 190 • 2017 ACR/ARHP Annual Meeting
Opioid Dispensation Among Systemic Lupus Erythematosus (SLE) Patients Who Persistently Frequent the Emergency Department (ED)
Jiha Lee¹, Lisa Gale Suter^2,3 and Liana Fraenkel^3,4, ¹Rheumatology, Yale University School of Medicine, New Haven, CT, New Haven, CT, ²Medicine, Rheumatol., TAC S541, Rheumatology, VA Connecticut Healthcare System, West Haven, CT, New Haven, CT, ³Rheumatology, Rheumatology, Yale University School of Medicine, New Haven, CT, New Haven, CT, ⁴Medicine, Section of Rheumatology, Rheumatology, VA Connecticut Healthcare System, West Haven, CT, New Haven, CT
Background/Purpose: Patients who persistently frequent the ED are more likely to be prescribed opioids for pain, and opioid initiation in the ED has been found…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].